EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Novel bivalent mucosal antigen formulation targeting SARS-CoV-2 and influenza: immunogenicity assessment using zan in vitro human nasal-associated lymphoid tissue model

W H Mahallawi

Polish Journal of Veterinary Sciences · 15.06.2026 · 29 (2)

DOI: 10.24425/pjvs.2026.1273 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Polish Journal of Veterinary Sciences, online erschienen am 15.06.2026. Verfasst von W H Mahallawi. Beteiligte Einrichtung: Clinical Laboratory Sciences Department, College of Applied Medical Sciences, Taibah University, Prince Nayef bin Abdulaziz Road, 42353, Madinah, Sau…. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19 Vaccines, Influenza A Virus, H1N1 Subtype, Antigens, Viral. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The development of mucosal vaccines is crucial for controlling the transmission of respiratory viruses such as SARS-CoV-2 and influenza at their point of entry. This study aimed to validate a human tonsil-derived in vitro model for screening antigen formulation candidates and to evaluate the immunogenicity of a novel bivalent formulation. Mononuclear cells (MNCs) isolated from human palatine tonsils (n=20) were stimulated with full-length SARS-CoV-2 spike (S) glycoprotein, influenza A (H1N1) hemagglutinin (HA), or a combination of both (bivalent) at a concentration of 20 μg/mL. After a 10-day culture, antigen-specific IgG, IgM, and IgA antibody levels were quantified by enzyme-linked immunosorbent assay (ELISA). Stimulation with individual antigens elicited robust polyisotypic antibody responses. The S protein induced significant fold-increases over unstimulated controls for IgG (8.23, p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2COVID-19 VaccinesInfluenza A Virus, H1N1 SubtypeAntigens, ViralInfluenza VaccinesInfluenza, HumanCOVID-19HumansPalatine TonsilHemagglutinin Glycoproteins, Influenza VirusAntibodies, ViralSpike Glycoprotein, Coronavirus

Substanzen

Hemagglutinin Glycoproteins, Influenza VirusAntibodies, ViralCOVID-19 VaccinesSpike Glycoprotein, CoronavirusAntigens, ViralInfluenza Vaccines

Autor:innen und Institutionen

  • Clinical Laboratory Sciences Department, College of Applied Medical Sciences, Taibah University, Prince Nayef bin Abdulaziz Road, 42353, Madinah, Saudi Arabia; Health and Life Research Center, Taibah University, Prince…

Zitieren

APA

Mahallawi, W. H. (2026). Novel bivalent mucosal antigen formulation targeting SARS-CoV-2 and influenza: immunogenicity assessment using zan in vitro human nasal-associated lymphoid tissue model. Polish Journal of Veterinary Sciences, 29(2). https://doi.org/10.24425/pjvs.2026.1273

Vancouver

Mahallawi WH. Novel bivalent mucosal antigen formulation targeting SARS-CoV-2 and influenza: immunogenicity assessment using zan in vitro human nasal-associated lymphoid tissue model. Polish Journal of Veterinary Sciences. 2026;29(2). doi:10.24425/pjvs.2026.1273

BibTeX
@article{Mahallawi2026,
  author = {Mahallawi, W H},
  title = {Novel bivalent mucosal antigen formulation targeting SARS-CoV-2 and influenza: immunogenicity assessment using zan in vitro human nasal-associated lymphoid tissue model},
  journal = {Polish Journal of Veterinary Sciences},
  year = {2026},
  volume = {29},
  number = {2},
  doi = {10.24425/pjvs.2026.1273}
}
Kostenlos starten →